GGrantIndex
← Leaderboards

Thomas M Roberts

Dana-Farber Cancer Institute

Google Scholar ↗PubMed ↗ORCID ↗
$29,815,975
Attributed
$32,919,101
Total exposure
17
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$32,919,101 · 17

By mechanism

R01$12,776,095 · 5
R35$7,129,589 · 1
P01$4,220,482 · 4
P50$3,686,545 · 4
RC2$2,653,695 · 1
T32$2,075,784 · 1

Top collaborators

Most similar at Dana-Farber Cancer Institute

Same institution · by research overlap

Others in their field

Top investigators on “Tumor”

Research focus

TumorGrantMalignant NeoplasmsProtein Isoforms1-Phosphatidylinositol 3-KinasePathway InteractionsSignal TransductionPten GeneCellsTumor Suppressor ProteinsPharmaceutical PreparationsOncogenesInhibitor/AntagonistGeneticResponseProteinsPhosphatidylinositide 3-Kinase InhibitorClinical TrialsMutationCell TransformationIn VivoEventLeadCombined Modality Therapy

Grant awards (70)

Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$1,049,779
R35 · FY2025 · CA · contact PI
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$997,290
R35 · FY2024 · CA · contact PI
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$1,028,782
R35 · FY2023 · CA · contact PI
Cancer Chemical Biology and Metabolism Training Program$359,150
T32 · FY2023 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$1,028,782
R35 · FY2022 · CA · contact PI
Cancer Chemical Biology and Metabolism Training Program$426,727
T32 · FY2022 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$1,049,779
R35 · FY2021 · CA · contact PI
Cancer Chemical Biology and Metabolism Training Program$381,671
T32 · FY2021 · CA
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway$332,063
P01 · FY2021 · CA · contact PI
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$1,049,779
R35 · FY2020 · CA · contact PI
Cancer Chemical Biology and Metabolism Training Program$462,866
T32 · FY2020 · CA
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway$332,063
P01 · FY2020 · CA · contact PI
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers$925,398
R35 · FY2019 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$537,433
R01 · FY2019 · CA · contact PI
Molecular mechanisms and therapeutic targeting of PI3K-p110beta/PTEN signaling in breast cancer and cancer immunity$497,522
R01 · FY2019 · CA · contact PI
Cancer Chemical Biology and Metabolism Training Program$445,370
T32 · FY2019 · CA
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway$322,101
P01 · FY2019 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2018 · CA · contact PI
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway$332,063
P01 · FY2018 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2017 · CA · contact PI
Targeting the PI3K Signaling Axis$428,993
P50 · FY2017 · CA · contact PI
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway$334,626
P01 · FY2017 · CA · contact PI
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer$242,707
P50 · FY2017 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2016 · CA · contact PI
Targeting the PI3K Signaling Axis$415,539
P50 · FY2016 · CA · contact PI
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer$252,047
P50 · FY2016 · CA · contact PI
Targeting the PI3K Signaling Axis$628,967
P50 · FY2015 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2015 · CA · contact PI
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer$273,207
P50 · FY2015 · CA · contact PI
Targeting the PI3K Signaling Axis$490,407
P50 · FY2014 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$368,331
R01 · FY2014 · CA · contact PI
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer$279,437
P50 · FY2014 · CA · contact PI
Targeting the PI3K Signaling Axis$404,673
P50 · FY2013 · CA · contact PI
The Role of Bub1 in SV40 Large T Mediated Transformation$360,732
P01 · FY2013 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$358,536
R01 · FY2013 · CA · contact PI
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer$270,568
P50 · FY2013 · CA · contact PI
The Role of Bub1 in SV40 Large T Mediated Transformation$388,212
P01 · FY2012 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$383,161
R01 · FY2012 · CA · contact PI
The Role of Bub1 in SV40 Large T Mediated Transformation$392,800
P01 · FY2011 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$384,951
R01 · FY2011 · CA · contact PI
Targeting PTEN Null Tumors via Inhibition of the p110beta Isoform of PI3 Kinase$1,350,835
RC2 · FY2010 · CA · contact PI
The Role of Bub1 in SV40 Large T Mediated Transformation$408,106
P01 · FY2010 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$396,128
R01 · FY2010 · CA · contact PI
Targeting PTEN Null Tumors via Inhibition of the p110beta Isoform of PI3 Kinase$1,302,860
RC2 · FY2009 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$415,944
R01 · FY2009 · CA · contact PI
The Role of Bub1 in SV40 Large T Mediated Transformation$401,659
P01 · FY2009 · CA · contact PI
Project 2 - Effects of Herb Fractions on Cell Function/Regulation:$116,213
U19 · FY2009 · CA · contact PI
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors$691,465
R01 · FY2008 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$405,626
R01 · FY2008 · CA · contact PI
Project 2 - Effects of Herb Fractions on Cell Function/Regulation:$106,810
U19 · FY2008 · CA · contact PI
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors$686,328
R01 · FY2007 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$403,444
R01 · FY2007 · CA · contact PI
Project 2 - Effects of Herb Fractions on Cell Function/Regulation:$98,502
U19 · FY2007 · CA · contact PI
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors$687,888
R01 · FY2006 · CA · contact PI
Molecular Mechanisms of Polyoma Induced Transformation$403,895
R01 · FY2006 · CA · contact PI
Project 2 - Effects of Herb Fractions on Cell Function/Regulation:$55,386
U19 · FY2006 · CA · contact PI
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors$684,760
R01 · FY2005 · CA
Molecular Mechanisms of Polyoma Induced Transformation$402,511
R01 · FY2005 · CA
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors$664,478
R01 · FY2004 · CA
MOLECULAR MECHANISMS OF POLYOMA INDUCED TRANSFORMATION$394,523
R01 · FY2004 · CA
MOLECULAR MECHANISMS OF POLYOMA INDUCED TRANSFORMATION$385,493
R01 · FY2003 · CA
MOLECULAR MECHANISMS OF POLYOMA INDUCED TRANSFORMATION$377,366
R01 · FY2002 · CA
SV40 LARGE T ANTIGEN J DOMAIN FUNCTION$228,401
P01 · FY2002 · CA
Evaluation of PI3K pathway and p110 in prostate cancer$103,677
P01 · FY2002 · CA
MOLECULAR MECHANISMS OF POLYOMA INDUCED TRANSFORMATION$369,910
R01 · FY2001 · CA
SV40 LARGE T ANTIGEN J DOMAIN FUNCTION$0
P01 · FY2001 · CA
Evaluation of PI3K pathway and p110 in prostate cancer$0
P01 · FY2001 · CA
MOLECULAR MECHANISMS OF POLYOMA INDUCED TRANSFORMATION$362,042
R01 · FY2000 · CA
SRC FAMILY OF NONRECEPTOR TYROSINE KINASES$298,148
R01 · FY2000 · CA
SV40 LARGE T ANTIGEN J DOMAIN FUNCTION$283,979
P01 · FY2000 · CA